Pediatric patients with congenital heart desease (CHD) and the need for surgical correction, e. g. atrial septal defect (Q 21.1) but also every other CHD. Q21.1
Conditions
Interventions
Group 1: Postoperative application of Cefotaxime for prophylaxis, duration of application 5 days (= 15 postoperative doses): weight adapted dosage, 100 mg/kg/d iv divided by 3 doses, maximum daily dos
Sponsors
Universitätsklinikum des Saarlandes
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: - Pediatric patients up to the age of 18 years with congenital heart disease and with the need of surgical intervention - Written consent of the parents/persons who have the care and custody of the children and, depending on the age, of the patients capable of insight, all children and adolescents aged 0 to 18 years
Exclusion criteria
Exclusion criteria: - Absent of written consent - Known allergic reactions or incompatibility of the planned antibiotics - Indication for delayed sternal closure - Known colonisation with multi-drug resistant bacteria - Antibiotic treatment within the last 7 days preoperatively
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Appearance of wound infections and other infections: - clinical assessment preoperatively, on admission to ICU and in the course of time in hospital - blood work preoperatively, on admission to ICU and day one and three postoperatively (e. g. CrP, Procalitonin, WBC) | — |
Secondary
| Measure | Time frame |
|---|---|
| - Positive culture from foreign bodies, i. e. CVL, thoracic drainage, tube, pacing wires - Duration of ventilation - Stay in ICU - Stay in hospital - CrP and Procalzitonin - Endocarditis up to 6 months postoperatively | — |
Countries
Germany
Contacts
Public ContactHarald Sauer
Universitätsklinikum des Saarlandes Klinik für Pädiatrische Kardiologie
Outcome results
None listed